



## Oncocyte to Report First Quarter 2020 Financial Results on Tuesday, May 12

May 05, 2020

IRVINE, Calif., May 05, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that it will release its financial and operating results for the first quarter ended March 31, 2020, on Tuesday, May 12, 2020, after the close of the U.S. financial markets. The Company will host a conference call on Tuesday, May 12, 2020, at 4:30 pm ET / 1:30 pm PT to discuss the results along with recent corporate developments.

The dial-in number in the U.S./Canada is 877-407-9716; for international participants, the number is 201-493-6779. For all callers, please refer to Conference ID 13703079. To access the live webcast, go to the investor relations section on the Company's website, or by clicking here:

<http://public.viavid.com/index.php?id=139620>.

### **About Oncocyte Corporation**

Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum, with the goal of improving patient outcomes by accelerating and optimizing diagnosis and treatment. The Company recently launched DetermaRx™, a treatment stratification test that enables the identification of early-stage lung cancer patients at high risk for recurrence post-resection, allowing them to be treated when their cancer may be more responsive to adjuvant chemotherapy. DetermaDx™, the company's liquid biopsy test in development, utilizes a proprietary immune system interrogation approach to clarify if a patients' lung nodules are benign, which may enable them to avoid potentially risky invasive diagnostic procedures. Oncocyte is also developing DetermaIO™, a gene expression test that identifies patients more likely to respond to checkpoint immunotherapies.

DetermaDx, DetermaRx and DetermaIO are trademarks of Oncocyte Corporation.

### **Investor Contact**

Bob Yedid  
LifeSci Advisors, LLC  
646-597-6989  
[bob@lifesciadvisors.com](mailto:bob@lifesciadvisors.com)

### **Media Contact**

Cait Williamson, Ph.D.  
LifeSci Communications, LLC

646-751-4366

[cait@lifescicomms.com](mailto:cait@lifescicomms.com)

Source: Oncocyte Corporation



Source: OncoCyte Corporation

